Waltham-based Repligen Corp., which produces products used in the manufacturing of biological drugs, reported quarterly revenue of $15.4 million, an 18.2 percent decrease from the year-earlier quarter, as adjusted earnings per share fell to 10 cents from 30 cents. Wall Street estimates had called for $15.9 million in revenue and 14 cents in per-share earnings. If there was a bright spot, Motley Fool reported, it was that bioprocessing revenue jumped nearly 7 percent to $10.4 million.
Repligen’s revenue slides 18.2 percent
